SCHEMBL6937058

SCHEMBL6937058

Cc1cc(NC(=O)Cc2cc(C#N)ccc2OCc2ccccc2)ccc1-n1c(CNC(=O)OC(C)(C)C)nc2ccccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.39
ALDH1A1 P00352 3/20 0.39
USP2 O75604 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP2C9 P11712 1/20 0.38
PTGER1 P34995 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
BRD4 O60885 2/20 0.37
P2RX4 Q99571 1/20 0.36
HCRTR1 O43613 1/20 0.35
RORC P51449 1/20 0.35
NSD2 O96028 1/20 0.35
TP53 P04637 1/20 0.35
PPIA P62937 1/20 0.35
SIRT2 Q8IXJ6 1/20 0.35
HPGD P15428 1/20 0.35
BCHE P06276 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7076172 0.80 MEN1 (0.45) LMNAALDH1A1USP2NPSR1L3MBTL1
SCHEMBL7122686 0.78 P2RX4 (0.44) LMNACYP2C9PTGER1P2RX4RORC
SCHEMBL7561577 0.76 CYP19A1 (0.42) LMNAALDH1A1USP2NPSR1L3MBTL1
SCHEMBL7560423 0.75 HPN (0.40) LMNAALDH1A1SMN1; SMN2BRD4TP53
SCHEMBL6330920 0.75 MRGPRX4 (0.47) LMNACYP2C9PTGER1PPIAMRGPRX4
SCHEMBL7127088 0.74 MRGPRX4 (0.49) LMNAALDH1A1NPSR1P2RX4RORC
SCHEMBL7120699 0.74 MET (0.38) CYP2C9PTGER1P2RX4HCRTR1RORC
SCHEMBL7121876 0.71 ALDH1A1 (0.49) LMNAALDH1A1L3MBTL1SMN1; SMN2P2RX4
SCHEMBL5099764 0.70 MET (0.46) LMNAALDH1A1P2RX4PPIAMRGPRX4
SCHEMBL6936342 0.70 GABRA1 (0.38) LMNAPTGER1P2RX4PPIAMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370540-A1 ANTI-THROMBOTIC CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENTS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2003-12-17 EP disclosed
US-20020183519-A1 Antithrombotic carboxylic acid amides BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-12-05 US disclosed
WO-2002072558-A1 ANTI-THROMBOTIC CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183519-A1 Antithrombotic carboxylic acid amides SERPINC1, TFPI, F2 LMNA 1079/4885ALDH1A1 83/4885USP2 3216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.